Isotonic Versus Hypotonic Fluid for Maintenance IV Therapy

This study has been completed.
Sponsor:
Information provided by:
McGill University Health Center
ClinicalTrials.gov Identifier:
NCT00457873
First received: April 5, 2007
Last updated: May 20, 2008
Last verified: May 2008

April 5, 2007
May 20, 2008
January 2007
April 2008   (final data collection date for primary outcome measure)
rate of change in serum sodium [ Time Frame: 8 to 20 hours ] [ Designated as safety issue: Yes ]
  • rate of change in serum sodium
  • hypertension
  • congestive heart failure
Complete list of historical versions of study NCT00457873 on ClinicalTrials.gov Archive Site
  • hypertension [ Time Frame: 8 to 20 hours ] [ Designated as safety issue: Yes ]
  • congestive heart failure [ Time Frame: 8 to 20 hours ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Isotonic Versus Hypotonic Fluid for Maintenance IV Therapy
Isotonic Versus Hypotonic Saline for Maintenance Intravenous Fluid Therapy: A Pilot Randomized Trial

Hyponatremia associated with administration of hypotonic intravenous (IV) fluids may have serious complications. It has recently been suggested that isotonic saline may be a more appropriate choice of maintenance IV fluid. This pilot and feasibility study aims to compare isotonic saline to 0.45% saline in hospitalized children requiring parenteral fluid support in order to:

Aim 1: To determine the feasibility of conducting a double-blind, randomized controlled trial comparing these solutions.

Aim 2a: To compare the rate of change in serum Na (mmol/L/hr) and the incidence of hyponatremia (Na <136 mmol/L) between patients receiving isotonic and hypotonic intravenous fluids at at least 50% of the traditional maintenance rate for an interval of at least 8 hours.

Aim 2b: To compare the incidence of adverse events between the two IV fluid treatment groups.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Gastroenteritis
  • Bronchiolitis
  • Sepsis
  • Urinary Tract Infection
  • Drug: 0.9% saline in 5% dextrose (intravenous)
    Other Name: isotonic saline
  • Drug: 0.45% saline in 5% dextrose (intravenous)
  • Experimental: A
    0.9% saline in 5% dextrose (intravenous)
    Intervention: Drug: 0.9% saline in 5% dextrose (intravenous)
  • Active Comparator: B
    0.45% saline in 5% dextrose (intravenous)
    Intervention: Drug: 0.45% saline in 5% dextrose (intravenous)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
April 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 1 month to 18 years of age
  • Require IV fluids for at least 8 hr.
  • Baseline serum sodium >=136 mmol/L & <=145 mmol/L

Exclusion Criteria:

  • Baseline serum sodium concentration less than 136 mmol/L or greater than 145 mmol/L
  • Renal disease, a history of cardiac dysfunction or evidence of cardiac dysfunction, pre-existing hypertension, diuretic use, edema, or known adrenal dysfunction
  • Acute neurological illness such as meningitis or encephalitis
  • Severe chronic neurological illnesses (uncontrolled seizure disorders, severe developmental delay)
Both
1 Month to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00457873
PED-06-016
Not Provided
Dr. Bethany Foster, Montreal Children's Hospital
McGill University Health Center
Not Provided
Principal Investigator: Bethany J Foster, MD, MSCE Montreal Children's Hospital Research Institute
McGill University Health Center
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP